Lyell Immunopharma, Inc. has announced a significant private placement of its common stock, raising approximately $80 million. This move is crucial for the company as it seeks to bolster its financial resources to support ongoing and future projects.

On November 3, 2026, the company entered into a Securities Purchase Agreement with institutional accredited investors. Under this agreement, Lyell Immunopharma agreed to sell 7,428,040 shares of its common stock at a price of $10.77 per share. The closing of this transaction is expected to occur on or about November 4, 2026, pending the satisfaction of customary closing conditions.

The total gross proceeds from this private placement are anticipated to be around $80 million before expenses. This funding is expected to enhance Lyell's financial stability and support its strategic initiatives in the pharmaceutical preparations sector.

The company is relying on an exemption from the registration requirements of the Securities Act of 1933, as amended, under Section 4(a)(2). Each investor involved in this transaction has provided representations suitable for a private placement of securities, and restrictive legends will be affixed to the shares issued.

As part of the Purchase Agreement, Lyell Immunopharma has committed to prepare and file a registration statement with the Securities and Exchange Commission within 30 days after the closing. This statement will register the shares for resale, ensuring compliance with regulatory requirements. The company has also acknowledged that cash penalties may apply in the event of registration failures.

This capital raise comes at a time when the pharmaceutical preparations industry is increasingly competitive, with companies continually seeking innovative financing solutions to fund research and development. Lyell Immunopharma's move may set a precedent for other firms in the sector looking to enhance their financial footing.

In summary, the successful completion of this private placement will provide Lyell Immunopharma with essential capital to advance its projects and strengthen its position in the pharmaceutical market.